These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 9590233)

  • 1. Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides.
    Antón LC; Snyder HL; Bennink JR; Vinitsky A; Orlowski M; Porgador A; Yewdell JW
    J Immunol; 1998 May; 160(10):4859-68. PubMed ID: 9590233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells.
    Cerundolo V; Benham A; Braud V; Mukherjee S; Gould K; Macino B; Neefjes J; Townsend A
    Eur J Immunol; 1997 Jan; 27(1):336-41. PubMed ID: 9022037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors: involvement of nonproteasomal cytosolic proteases in antigen processing?
    Vinitsky A; Antón LC; Snyder HL; Orlowski M; Bennink JR; Yewdell JW
    J Immunol; 1997 Jul; 159(2):554-64. PubMed ID: 9218569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MHC class I-associated peptides produced from endogenous gene products with vastly different efficiencies.
    Anton LC; Yewdell JW; Bennink JR
    J Immunol; 1997 Mar; 158(6):2535-42. PubMed ID: 9058784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presentation of viral antigens restricted by H-2Kb, Db or Kd in proteasome subunit LMP2- and LMP7-deficient cells.
    Zhou X; Momburg F; Liu T; Abdel Motal UM; Jondal M; Hämmerling GJ; Ljunggren HG
    Eur J Immunol; 1994 Aug; 24(8):1863-8. PubMed ID: 8056044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides.
    Mo XY; Cascio P; Lemerise K; Goldberg AL; Rock K
    J Immunol; 1999 Dec; 163(11):5851-9. PubMed ID: 10570269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective involvement of proteasomes and cysteine proteases in MHC class I antigen presentation.
    López D; Del Val M
    J Immunol; 1997 Dec; 159(12):5769-72. PubMed ID: 9550370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel dipeptide aldehydes are proteasome inhibitors and block the MHC-I antigen-processing pathway.
    Harding CV; France J; Song R; Farah JM; Chatterjee S; Iqbal M; Siman R
    J Immunol; 1995 Aug; 155(4):1767-75. PubMed ID: 7636233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific proteolytic cleavages limit the diversity of the pool of peptides available to MHC class I molecules in living cells.
    Serwold T; Shastri N
    J Immunol; 1999 Apr; 162(8):4712-9. PubMed ID: 10202012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome activity limits the assembly of MHC class I molecules after IFN-gamma stimulation.
    Benham AM; Neefjes JJ
    J Immunol; 1997 Dec; 159(12):5896-904. PubMed ID: 9550386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MHC-encoded proteasome subunits LMP2 and LMP7 are not required for efficient antigen presentation.
    Yewdell J; Lapham C; Bacik I; Spies T; Bennink J
    J Immunol; 1994 Feb; 152(3):1163-70. PubMed ID: 8301122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A role for the proteasome regulator PA28alpha in antigen presentation.
    Groettrup M; Soza A; Eggers M; Kuehn L; Dick TP; Schild H; Rammensee HG; Koszinowski UH; Kloetzel PM
    Nature; 1996 May; 381(6578):166-8. PubMed ID: 8610016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein.
    Yellen-Shaw AJ; Wherry EJ; Dubois GC; Eisenlohr LC
    J Immunol; 1997 Apr; 158(7):3227-34. PubMed ID: 9120278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD8+ T cell cross-priming via transfer of proteasome substrates.
    Norbury CC; Basta S; Donohue KB; Tscharke DC; Princiotta MF; Berglund P; Gibbs J; Bennink JR; Yewdell JW
    Science; 2004 May; 304(5675):1318-21. PubMed ID: 15166379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential roles of protein oxidation and the immunoproteasome in MHC class I antigen presentation: the 'PrOxI' hypothesis.
    Teoh CY; Davies KJ
    Arch Biochem Biophys; 2004 Mar; 423(1):88-96. PubMed ID: 14871471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-proteasomal antigen processing for major histocompatibility complex class I presentation.
    Rock KL; York IA; Goldberg AL
    Nat Immunol; 2004 Jul; 5(7):670-7. PubMed ID: 15224092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL.
    Deng Y; Yewdell JW; Eisenlohr LC; Bennink JR
    J Immunol; 1997 Feb; 158(4):1507-15. PubMed ID: 9029084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation.
    Grant EP; Michalek MT; Goldberg AL; Rock KL
    J Immunol; 1995 Oct; 155(8):3750-8. PubMed ID: 7561079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence signals for generation of antigenic peptides by the proteasome: implications for proteasomal cleavage mechanism.
    Altuvia Y; Margalit H
    J Mol Biol; 2000 Jan; 295(4):879-90. PubMed ID: 10656797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein.
    Gileadi U; Moins-Teisserenc HT; Correa I; Booth BL; Dunbar PR; Sewell AK; Trowsdale J; Phillips RE; Cerundolo V
    J Immunol; 1999 Dec; 163(11):6045-52. PubMed ID: 10570292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.